A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics, Safety and Tolerability of RO4917523 Conducted in 2 Phases: a Single-Dose, Cross-Over Administration to Healthy Japanese Subjects and a Multiple-Dose Administration to Healthy Japanese and Caucasian Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2015
At a glance
- Drugs Basimglurant (Primary)
- Indications Fragile X syndrome; Major depressive disorder
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Roche
- 15 Nov 2011 Planned end date changed from 1 Oct 2011 to November 2011 as reported by ClinicalTrials.gov.
- 14 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Sep 2011 Planned end date changed from 1 Dec 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.